PTN Palatin Technologies, Inc. Comm

0.38
-0.00  -0%
Previous Close 0.38
Open 0.39
Price To book 0.00
Market Cap 52.42M
Shares 137,947,000
Volume 794,131
Short Ratio 4.38
Av. Daily Volume 2,151,220

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 1, 2016. NDA filing due 1Q 2018.
Rekynda (Bremelanotide)
Female sexual dysfunction (FSD)
Phase 2 planned for 1H 2017
PL-3994
Heart failure

Latest News

  1. Edited Transcript of PTN earnings conference call or presentation 16-May-17 3:00pm GMT
  2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
  3. Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
  4. Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York City at the Essex House
  5. Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
  6. Palatin Technologies To Present At The 29th Annual ROTH Conference
  7. AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting
  8. Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q2, 2017 By the Numbers
  9. AMAG Pharmaceuticals Inks $60M Drug Deal
  10. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017
  11. Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™
  12. Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy?
  13. Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™
  14. AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal
  15. AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
  16. Why AMAG Pharmaceuticals, Inc. Is Falling Today
  17. How CytRx Corporation (CYTR) Stacks Up Against Its Peers
  18. Palatin Technologies Closes on $16.5 Million Financing